Analysis of Tissue and Serum MicroRNA Expression in Patients with Upper Urinary Tract Urothelial Cancer

Kriebel, Stephanie; Schmidt, Doris; Holdenrieder, Stefan; Goltz, Diane; Kristiansen, Glen; Moritz, Rudolf; Fisang, C.; Müller, Stefan; Ellinger, Jörg

doi:10.1371/journal.pone.0117284

Cited by 45 publications

(32 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Scheffer et al (12) confirmed that the expression of 22 miRNAs in bladder cancer tissues was upregulated, including miR-96. Kriebel et al (11) reported that the expression of plasma miR-96 in patients with bladder cancer was significantly increased. Eissa et al (26) demonstrated that miR-96 was highly expressed in bladder cancer tissues, but not in benign bladder tumors.…”

Section: Discussionmentioning

confidence: 99%

“…miR-96 is a conserved miRNA that may be involved in the occurrence and development of bladder cancer (9,10). Further research also demonstrated that miR-96 was highly expressed in bladder cancer tissue and the blood plasma obtained from patients with bladder cancer (11)(12)(13). Yamada et al (14) confirmed that miR-96 expression in urine samples from bladder urothelial carcinoma was significantly increased compared with that from healthy subjects.…”

Section: Introductionmentioning

confidence: 94%

See 1 more Smart Citation

Anticancer effect of miR-96 inhibitor in bladder cancer cell lines

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Abstract. The present study aimed to investigate the role of microRNA-96 (miR-96) in the proliferation, invasion and apoptosis of bladder cancer cell lines, and the associated mechanisms. The expression of miR-96 and human ether-à-go-go-related (HERG1) potassium channel in the normal uroepithelium SV-HUC-1 cell line, and bladder cancer T24 and 5637 cell lines were examined using reverse transcription-polymerase chain reaction or/and western blotting. Transfection with miR-96 inhibitor or scrambled control (SC) was used to study the biological activities of miR-96 in bladder cancer cell lines. MTT, flow cytometric and Transwell assays were applied to detect cell viability, apoptosis and invasion, respectively. A dual-luciferase reporter assay was applied to determine the association between miR-96 and HERG1 expression. As demonstrated, miR-96 was highly expressed in the two bladder cancer cell lines, particularly in T24 cells. Following transfection with miR-96 inhibitor, miR-96 expression was significantly reduced in the T24 cell line, compared with SC. The miR-96 inhibitor suppressed cell proliferation and invasion, promoted apoptosis and arrested the cell cycle at the G 1 phase. Consistently, HERG1 was also highly expressed in the two bladder cancer cell lines at the mRNA and protein level, but not in the normal uroepithelium cell line. The miR-96 inhibitor also significantly decreased HERG1 expression compared with SC. The results of the dual-luciferase reporter assay indicated that miR-96 directly targeted wild-type HERG1. In conclusion, miR-96 inhibitor exhibited anticancer effects on bladder cancer cells by inhibiting proliferation and invasion of cells, and promoting their apoptosis. HERG1 was an important target of miR-96. These results provided experimental evidence supporting miR-96 as a therapeutic target for patients with bladder cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 94%

Anticancer effect of miR-96 inhibitor in bladder cancer cell lines

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Using deep-sequencing analysis, we found that miR-141-3p expression was decreased by 1.26-fold in early PCa compared to that in BPH (P < 0.05), and confirmed a similar 1.17-fold decrease in early PCa compared to that in BPH (P = 0.2053) by qRT-PCR. In addition, miR-141-3p expression levels vary in different tumors, with overexpression observed in bladder [16], urothelial [17], breast [18] [19], ovarian [20], endometrioid [21], cholangiocytes [22] and colorectal cancers [23] and NSCLC [24], while expression is downregulated in gastric cancer [25], hepatocellular carcinomas [26] [27], renal cell carcinoma [28], lymphatic metastatic pancreatic cancer [29], pituitary tumors [30], craniopharyngioma [31], head and neck cancer [32], osteosarcoma [33], and cutaneous T cell lymphoma [34]. These reports provide compelling evidence for a role of miR-141-3p as an oncogene or tumor suppressor in different tumors and at different stages.…”

Section: Discussionmentioning

confidence: 99%

miR-141-3p Suppresses Expression of Androgen Receptors and Functions as a Tumor Suppressor Gene in Prostate Carcinogenesis

Song¹,

Chen²,

Wang³

et al. 2017

IJCM

View full text Add to dashboard Cite

Background: Prostate cancer (PCa) is a leading cause of tumor mortality in Western societies. In China, the PCa mortality rate is increasing yearly. Androgen receptors (ARs) and microRNAs (miRNAs) play central roles in prostate carcinogenesis and progression. Methods: To characterize the underlying molecular mechanisms, we compared the miRNA profiles of early PCa (G ≤ 7), advanced PCa (G > 7) and non-tumor prostate tissues using deep-sequencing. The target genes of differentially expressed miRNAs were predicted by bioinformatics analysis and confirmed by luciferase reporter assays and Western blot (WB) and quantitative reverse transcription-PCR (qRT-PCR)analyses. Finally, we performed in vitro functional studies by inducing or inhibiting miR-141-3p expression using an artificial mimic or inhibitor. Results: A computational search implicated the open reading frame (ORF) of AR mRNA as a potential miR-141-3p target site. The qRT-PCR, WB and luciferase reporter assays revealed a reverse regulatory effect of miR-141-3p on AR. Mutation of the potential miR-141-3p binding site in the AR ORF resulted in a loss of responsiveness to the corresponding miRNA. Moreover, miR-141-3p expression levels were unchanged in early PCas, but were obviously increased in advanced PCas. MiR-141-3p overexpression inhibited RWPE-1 cell proliferation, mobility, and prohibited the entry of cells into the G2-S-M phase; miR-141-3p inhibition had the inverse effects. At the same time, we tested miR-141-3p's functions in PC-3 and VCaP prostate cancer cell lines. Conclusions: Taken together, our results indicate that miR-141-3p targets AR and its downstream signaling pathways, and functions as a tumor suppressor miR in PCa carcinogenesis by suppressing cell growth and mobility, but the effect is not significant in maglinant PCas. MiR-141-3p is implicated as a novel therapeutic target for early PCa.

show abstract

“…These single-stranded sequences typically down regulate expression of mRNAs for tumorigenesis control, so they can potentially be utilized as cancer biomarkers and indicate the presence of an invasive tumor [8,9]. Detection can be applied to a clinical setting for minimal invasiveness because microRNAs can be observed in body fluids and they can maintain stability against changes in pH, RNase activity and temperature changes.…”

Section: Introductionmentioning

confidence: 99%

“…Detection can be applied to a clinical setting for minimal invasiveness because microRNAs can be observed in body fluids and they can maintain stability against changes in pH, RNase activity and temperature changes. As a result, microRNAs have been useful in diagnoses of bladder, kidney, prostate and testicular cancers [8,10]. There are still challenges for microRNAs in its applications, as it can be difficult to assay for miRNA and miRNAs may affect multiple genes that are not of interest [11].…”

Section: Introductionmentioning

confidence: 99%

Tissue microRNAs as Cancer Tissue Biomarkers

Upadhya¹

2017

J Tissue Sci Eng

View full text Add to dashboard Cite

AbstractmicroRNA (miRNA) is non-coding RNA sequences that modify DNA, typically through cleavages. They can have an effect on cell cycle progression, namely through inhibiting regulators for tumorigenesis control. Because of this, specific miRNA sequences can be monitored for cancer detection purposes. This detection is conducted through a variety of methods, such as in tissue, blood plasma, serum, ductal lavage fluid and nipple aspirate fluid. Recent research has been done to compare miRNA detection accuracy between these methods, especially with tissue analyses since this tends to be more invasive. Imaging methods have been utilized for cancer detection, but they are less effective in staging cancers, which is necessary for clinicians to provide individualized treatments. In several cases, detection accuracy has been compared to the accuracy from biopsy methods, which is a common practice but also invasive. In the future, non-invasive techniques of detection and personalized treatments will be the emphasis of research in cancer detection.

show abstract

Analysis of Tissue and Serum MicroRNA Expression in Patients with Upper Urinary Tract Urothelial Cancer

Cited by 45 publications

References 41 publications

Anticancer effect of miR-96 inhibitor in bladder cancer cell lines

Anticancer effect of miR-96 inhibitor in bladder cancer cell lines

miR-141-3p Suppresses Expression of Androgen Receptors and Functions as a Tumor Suppressor Gene in Prostate Carcinogenesis

Tissue microRNAs as Cancer Tissue Biomarkers

Contact Info

Product

Resources

About